eGenesis

eGenesis, Inc. is a biotechnology company based in Massachusetts, founded in 2015. The company focuses on genome engineering to develop transplantable human organs, cells, and tissues, aiming to address the global organ shortage and improve treatments for organ failure. Utilizing its proprietary EGEN™ Platform, eGenesis employs advanced CRISPR technology to make precise genetic modifications to donor organs, primarily from pigs. This innovative approach helps prevent rejection and enhances the safety and efficacy of these organs for human transplantation. eGenesis is advancing programs for kidney, liver, and heart transplants, as well as therapies for islet cell transplantation to treat type 1 diabetes. The company is dedicated to providing solutions for patients worldwide who are in urgent need of transplants. With a strong commitment to innovation and patient outcomes, eGenesis is actively working to transform the landscape of organ transplantation.